

# JOIN US FOR A DUAL SPEAKER PROGRAM

**NOW APPROVED**  
**QULIPTA**<sup>™</sup>  
(atogepant) tablets



**UBRELVY**<sup>®</sup>  
(ubrogepant) tablets | 50mg  
100mg



## AbbVie Offers Innovated Treatments For Migraine Patients



**PRESENTED BY:**  
**Jill Cramer, MD**

Blacksburg Neurology, PC  
Christiansburg, VA

**Thursday, May 12, 2022 at 6:30 PM CT**

**Flatiron Grille**

1160 Vann Dr., Jackson, TN 38305

**Please RSVP for this program using the following link:**  
**<https://migrainelive.com/register/142930>**

**MedForce can accept RSVPs via phone at (888) 616-0377. Please reference Meeting ID 142930.**

For questions, contact your AbbVie Representative Crystal Reasons Phone: (731) 676-3577 Email: [crystal.reasons@abbvie.com](mailto:crystal.reasons@abbvie.com)

### INDICATION

QULIPTA<sup>™</sup> (atogepant) is indicated for the preventive treatment of episodic migraine in adults.

### IMPORTANT SAFETY INFORMATION

**Adverse Reactions:** The most common adverse reactions (at least 4% and greater than placebo) are nausea, constipation, and fatigue.

**Please see accompanying full Prescribing Information or visit**  
**[https://www.rxabbvie.com/pdf/qulipta\\_pi.pdf](https://www.rxabbvie.com/pdf/qulipta_pi.pdf)**

### INDICATION

UBRELVY<sup>®</sup> (ubrogepant) is indicated for the acute treatment of migraine with or without aura in adults. UBRELVY is not indicated for the preventive treatment of migraine.

### IMPORTANT SAFETY INFORMATION

**Contraindication:** Concomitant use of strong CYP3A4 inhibitors (eg, ketoconazole, itraconazole, clarithromycin).

**Adverse Reactions:** The most common adverse reactions were nausea (4% vs 2% placebo) and somnolence (3% vs 1% placebo).

**Please see accompanying full Prescribing Information or visit**  
**[https://www.rxabbvie.com/pdf/ubrelvy\\_pi.pdf](https://www.rxabbvie.com/pdf/ubrelvy_pi.pdf)**

This promotional event is brought to you by AbbVie and is not certified for continuing medical education.

The speaker is a paid consultant presenting on behalf of AbbVie and the information being presented is consistent with FDA guidelines. This event is conducted in accordance with the PhRMA Code on Interactions with Healthcare Professionals and is limited to invited healthcare professionals (HCPs). Attendance by guests or spouses is not appropriate. It is AbbVie's policy to include only those healthcare professionals involved in patient care consistent with our product indication(s).

The cost of meals and refreshments provided to U.S. HCPs may be subject to public disclosure. AbbVie's disclosure will allocate the cost of meals and refreshments equally across all attendees regardless of actual consumption. AbbVie abides by applicable federal and state laws, which prohibit or limit the ability of government employees and certain healthcare professionals to accept items of value from AbbVie. Please comply with applicable law.

QULIPTA<sup>™</sup> and its design are trademarks of Allergan Pharmaceuticals International Limited, an AbbVie company.  
UBRELVY<sup>®</sup> and its design are registered trademarks of Allergan Pharmaceuticals International Limited, an AbbVie company.  
© 2021 AbbVie. All rights reserved. MBD150259 09/21

**abbvie**